Table 2 Baseline clinical and demographic characteristics of the study cohort, as well as compliance and radiographic response (RECIST) to chemotherapy
From: Safety and feasibility of fasting in combination with platinum-based chemotherapy
Characteristic | Median (range) | Number (%) |
|---|---|---|
Age | 61 (31–75) | |
Gender | Female | 17 (85 %) |
Male | 3 (15 %) | |
Race | Caucasian | 8 (40 %) |
Hispanic | 9 (45 %) | |
Black | 2 (10 %) | |
Asian | 1 (5 %) | |
ECOG Performance Status | 0 | 12 (60 %) |
1 | 8 (40 %) | |
Total Fasting Cycles Completed | 1 | 3 (15 %) |
2 | 15 (75 %) | |
>2 | 2 (10 %) | |
Best objective (RECIST) response | CR | 2 (10 %) |
PR | 6 (30 %) | |
SD | 3 (15 %) | |
PD | 1 (5 %) | |
N/A0 (adjuvant therapy) | 8 (40 %) |